IMMUTEP LIMITED - AMER

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

29 10 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report & Appendix 4C

28 10 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep to Present Phase II TACTI-002 Data at SITC 2021

01 10 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

29 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

28 9 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

21 9 2021 07:38:03 提供 Nasdaq GlobeNewswire

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

01 9 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

31 8 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

27 8 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 8 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 7 2021 07:00:03 提供 Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 7 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Reveals a New Anti-LAG-3 Research Program

08 6 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

04 6 2021 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

02 6 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

01 6 2021 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

26 5 2021 07:00:01 提供 Nasdaq GlobeNewswire